Bovine lactoferrin for the prevention of COVID-19 infection in health care personnel: a double-blinded randomized clinical trial (LF-COVID)
Early terminated low-risk patient prophylaxis RCT in Peru, showing no significant difference in cases with lactoferrin. There were no moderate or severe cases.
risk of symptomatic case, 58.7% higher, RR 1.59, p = 0.34, treatment 11 of 104 (10.6%), control 7 of 105 (6.7%).
|
risk of case, 23.4% higher, RR 1.23, p = 0.65, treatment 11 of 104 (10.6%), control 9 of 105 (8.6%).
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Navarro et al., 7 Dec 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Peru, peer-reviewed, median age 37.0, 14 authors, study period October 2020 - February 2021, trial
NCT04526821 (history) (LF-COVID).
Contact:
theresa.ochoa@upch.pe.
Abstract: Biometals
https://doi.org/10.1007/s10534-022-00477-3
Bovine lactoferrin for the prevention of COVID‑19 infection
in health care personnel: a double‑blinded randomized
clinical trial (LF‑COVID)
Rafaella Navarro · Jose Luis Paredes · Lourdes Tucto · Carlos Medina · Eddie Angles‑Yanqui ·
Juan Carlos Nario · Jorge Ruiz‑Cabrejos · Juan Luis Quintana · Kevin Turpo‑Espinoza ·
Fernando Mejia‑Cordero · Meylin Aphang‑Lam · Jorge Florez · Gabriel Carrasco‑Escobar ·
Theresa Jean Ochoa
Received: 30 March 2022 / Accepted: 24 November 2022
© The Author(s), under exclusive licence to Springer Nature B.V. 2022
Abstract Lactoferrin (LF) has in vitro antiviral
activity against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2). This study aimed to
determine the effect of bovine lactoferrin (bLF) in
the prevention of SARS-CoV-2 infection in health
care personnel. A randomized, double-blinded, placebo-controlled clinical trial was conducted in two
tertiary hospitals that provide care to patients with
SARS-CoV-2 infection in Lima, Peru. Daily supplementation with 600 mg of enteral bLF versus placebo
for 90 days was compared. Participants were weekly
screened for symptoms suggestive of SARS-CoV-2
infection and molecular testing was performed on
Navarro Rafaella and Paredes Jose Luis have contributed
equally to this work and share first authorship.
Supplementary Information The online version
contains supplementary material available at https://doi.
org/10.1007/s10534-022-00477-3.
R. Navarro · J. L. Paredes · L. Tucto · J. C. Nario ·
J. L. Quintana · K. Turpo‑Espinoza · T. J. Ochoa (*)
Laboratorio de Infectologia Pediátrica, Instituto de
Medicina Tropical Alexander von Humboldt, Universidad
Peruana Cayetano Heredia, Lima, Peru
e-mail: theresa.ochoa@upch.pe
R. Navarro · J. L. Paredes · C. Medina · E. Angles‑Yanqui ·
J. C. Nario · J. L. Quintana · K. Turpo‑Espinoza ·
F. Mejia‑Cordero · M. Aphang‑Lam · J. Florez ·
T. J. Ochoa
Facultad de Medicina Alberto Hurtado, Universidad
Peruana Cayetano Heredia, Lima, Peru
suspected episodes. A serological test was obtained
from all participants at the end of the intervention.
The main outcome included symptomatic and asymptomatic cases. A sub-analysis explored the time to
symptomatic infection. Secondary outcomes were
the severity, frequency, and duration of symptomatic
infection. The study was prematurely cancelled due
to the availability of vaccines against SARS-CoV-2
in Peru. 209 participants were enrolled and randomized, 104 received bLF and 105 placebo. SARSCoV-2 infection occurred in 11 (10.6%) participants
assigned to bLF and in 9 (8.6%) participants assigned
to placebo without significant differences (Incidence
Rate Ratio = 1.23, 95%CI 0.51–3.06, p-value = 0.64).
There was no significant effect of bLF on time to
symptomatic infection (Hazard Ratio = 1.61, 95%CI
0.62–4.19, p-value = 0.3). There were no significant
C. Medina · F. Mejia‑Cordero
Hospital Cayetano Heredia, Lima, Peru
E. Angles‑Yanqui · M. Aphang‑Lam · J. Florez
Hospital Nacional Arzobispo Loayza, Lima, Peru
J. Ruiz‑Cabrejos · G. Carrasco‑Escobar
Laboratorio de Innovación en Salud, Instituto de Medicina
Tropical Alexander von Humboldt, Universidad Peruana
Cayetano Heredia, Lima, Peru
T. J. Ochoa
School of Public Health, University of Texas Health
Science Center at Houston, Houston, TX, USA
Vol.: (0123456789)
13
Biometals
differences in secondary outcomes. A significant
effect of bLF in preventing SARS-CoV-2 infection
was not..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit